As revealed during the 2017 European Society of Cardiology Congress, the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) study demonstrated that in patients with atrial fibrillation post-percutaneous coronary intervention, anticoagulation using a combination of dabigatran and either ticagrelor or clopidogrel resulted in lower bleeding than traditional triple therapy with no increase in adverse events.

Keywords: Angiography, Ticlopidine, Atrial Fibrillation, Antithrombins, Hemorrhage, Cardiology

< Back to Listings